Compliance updated on Apr 15, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Oncolytics Biotech Inc

ONCY ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.50

▼ -2.19%

Market Cap $65.59M · Vol 45.56K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$65.59M

Micro Cap

Div Yield

N/A

EPS Growth

-24.65%

YoY

RSI (14)

30.59

Momentum

Beta

1.21

vs Market

52W High

$1.32

61.11% below

52W Low

$0.44

15.70% above

Volume

45.56K

Avg 114.23K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

98.01%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Oncolytics Biotech Inc (ONCY) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ONCY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.66%

-29.88%

-39.56%

-56.50%

YTD

-42.77%

-57.61%

-70.40%

-77.67%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-28,759,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-273.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	-24.65%
Outstanding Shares	131.12M

Technical Indicators

50-Day SMA	$0.71
200-Day SMA	$0.88
RSI (14)	30.59
Beta	1.21
52-Week High	$1.32
52-Week Low	$0.44

Volume Today	45.56K
Avg Daily Volume (30D)	114.23K
Relative Volume	0.40x
Volatility (10D)	108.13
Volatility (30D)	78.68
Free Float	98.01%

Analyst Consensus

BUY

Current Price $0.50

Mean Target $4.63

52W Low$0.44 52W High$1.32

Current

Target

$0.44 $1.32

Current Analyst target

+824.63% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIN/A

ISINUS68237V1035

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.74% ONC BeOne Medicines AG -1.08% 068270.KS Celltrion, Inc. -1.67% MEDP Medpace Holdings, Inc. -1.29% CRL Charles River Laboratories International, Inc. -1.51%

Company Profile

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a range of oncology treatments. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically cold tumors hot through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers.